Showing 441 - 460 results of 146,713 for search '(( 10 ((mg decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (mean decrease)) ))', query time: 0.89s Refine Results
  1. 441
  2. 442
  3. 443
  4. 444

    Numbers of all fractures occurring in men, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age. by Camilla Bergh (9904522)

    Published 2020
    “…<p>Numbers of all fractures occurring in men, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age.…”
  5. 445

    Numbers of all fractures occurring in women, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age. by Camilla Bergh (9904522)

    Published 2020
    “…<p>Numbers of all fractures occurring in women, arranged in order of decreasing mean age, and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age.…”
  6. 446
  7. 447
  8. 448
  9. 449

    Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF by Renée H. Fiechter (10230473)

    Published 2021
    “…No serious adverse events occurred. We observed numerical decreases of all infiltrating cell subtypes at week 12, reaching statistical significance for CD68+ sublining macrophages. …”
  10. 450

    Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3‑Oxo-3,4-dihydro‑2<i>H</i>‑ben... by Shuhei Ikeda (2380180)

    Published 2021
    “…Optimization of the left hand side afforded <b>4f</b> as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC<sub>50</sub> 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.…”
  11. 451
  12. 452

    S10 Data - by Christoph Anders (4068499)

    Published 2024
    “…The study was conducted with 25%, 50%, and 75% of the upper body weight. Additionally, we varied the starting point (forward tilt and backward tilt) and the direction of rotation. …”
  13. 453

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  14. 454

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  15. 455
  16. 456
  17. 457
  18. 458
  19. 459
  20. 460